

ForPatients

by Roche

Skin Cancer Advanced Melanoma

A Study to Evaluate The Efficacy And Safety Of RO7198457 In Combination With Pembrolizumab Versus Pembrolizumab Alone In Participants With Previously Untreated Advanced Melanoma.

A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma.

| | | |
|---|-------------------------------------|---|
| Trial Status Active, not recruiting | Trial Runs In 2 Countries | Trial Identifier NCT03815058 IMCODE001, 2018-001773-24 GO40558 |
|---|-------------------------------------|---|

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

Trial Summary:

This study will evaluate the efficacy, safety, pharmacokinetics, and patient-reported outcomes (PROs) of autogene cevumeran (RO7198457) plus pembrolizumab compared with pembrolizumab alone in patients with previously untreated advanced melanoma.

| | |
|-----------------------------------|-------------------------|
| Genentech, Inc. Sponsor | Phase 2 Phase |
|-----------------------------------|-------------------------|

NCT03815058 IMCODE001, 2018-001773-24 GO40558
Trial Identifiers

Eligibility Criteria:

| | | |
|----------------------|-------------------------|---------------------------------|
| Gender All | Age ≥18 Years | Healthy Volunteers No |
|----------------------|-------------------------|---------------------------------|
